DCGI nod for device-aided therapy for Parkinson’s patients

Parkinson’s disease is a movement disorder affecting about 12 lakh people in India


Last Updated on November 10, 2021 by The Health Master

DCGI nod for device-aided therapy for Parkinson’s patients

Hyderabad: Drug Controller General of India (DCGI) has given licence for new device-aided therapy for Parkinson’s disease.

London-based researchers and Nizam’s Institue of Medical Sciences (NIMS) doctors’ research paper has revealed that personalised treatment could be done with device-aided therapy using wearable sensors in advanced Parkinson’s disease.

Dr Vinod Metta, one of the lead researchers, said, “Parkinson’s disease is a movement disorder affecting about 12 lakh people in India.

Currently, only oral medications are available in India, and they are not effective in treating the symptoms.”

“Oral medications are helpful in the initial years, but as the patient ages, their disease progresses, leaving them crippled and compromising their quality of life.

Technology-driven device-aided therapy with apomorphine medicine given as subcutaneous injections and pumps has been a proven therapy for advanced stages of Parkinson’s disease and been successfully used in the West,” he added.

Multiple studies have demonstrated the high efficiency of apomorphine in treating the motor symptoms of Parkinson’s disease.


Apomorphine is delivered through devices as an intermittent therapy or continuous infusion therapy. Intermittent therapy is delivered using a pen device similar to that of an insulin pen. Continuous therapy is delivered using a pump which is similar to an insulin infusion pump,” Vinod Metta said.

“Apo pen injections works within 6-10 minutes and last for 90 minutes, these can be used as a rescue injections whereas Apo pump with continuous infusion is able to help patients as long as infusion in place, ideally most of the patients were given wakeful hours so that they no need to keep pump overnight,” the researcher said.

Around 40% of current Parkinson’s patients were believed to be eligible for device-aided therapies.

Apomorphine injection & infusion should be considered before even referring Parkinson’s patients to more conventional deep-brain surgeries say experts.

Drug Controller General of India permission was given to Hyderabad-based Celera Pharma Private Limited along with Germany-based EVER Neuro Pharma.

NFI 2021: Salient features of 6th Edition of National Formulary of India

Indian Pharmacopoeia Commission (IPC)

Govt allows import of Oxytocin API: Read details

NPPA should permit ceiling prices according to API price changes: SPIC

PLI scheme for Pharma Sector has potential to make India a…

FDA Haryana: Webinar organized for the Chemists of Haryana

Govt releases draft policy for R&D, Pharma and Medical Devices

Govt extends validity of licences of Distilleries to mfr Hand Sanitizer

Procedure to obtain license for manufacturing of Homoeopathic Medicines

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner